Bernd Heinrich

List of Publications by Year
in descending order

28 papers	2,401 citations	471509 17 h-index	610901 24 g-index
28 all docs	28 docs citations	28 times ranked	3677 citing authors

#	Article	IF	Citations
1	The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma. Gut, 2022, 71, 1161-1175.	12.1	60
2	NAFLD indirectly impairs antigen-specific CD8+ TÂcell immunity against liver cancer in mice. IScience, 2022, 25, 103847.	4.1	12
3	Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. Journal of Hepatology, 2022, 77, 748-760.	3.7	57
4	Innate lymphoid cells at the crossroadsÂof innate and adaptive immunity. Hepatology, 2022, 76, 903-905.	7.3	0
5	Plasticity of Innate Lymphoid Cells in Cancer. Frontiers in Immunology, 2022, 13, .	4.8	1
6	Steatohepatitis Impairs T-cellâ€“Directed Immunotherapies Against Liver Tumors in Mice. Gastroenterology, 2021, 160, 331-345.e6.	1.3	46
7	Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis. Journal of Hepatology, 2021, 74, 700-715.	3.7	60
8	Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. Cellular and Molecular Immunology, 2021, 18, 112-127.	10.5	159
9	CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma. Journal of Hepatology, 2021, 74, 1145-1154.	3.7	76
10	Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma. Cancer Discovery, 2021, 11, 1248-1267.	9.4	117
11	Hydroxychloroquine can impair tumor response to anti-PD1 in subcutaneous mouse models. IScience, 2021, 24, 101990.	4.1	11
12	Antiâ€“PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 1166-1178.	4.5	15
13	Activating Mucosal-Associated Invariant T Cells Induces a Broad Antitumor Response. Cancer Immunology Research, 2021, 9, 1024-1034.	3.4	29
14	Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients. United European Gastroenterology Journal, 2020, 8, 444-452.	3.8	9
15	Combined locoregional-immunotherapy for liver cancer. Journal of Hepatology, 2019, 70, 999-1007.	3.7	146
16	Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma. Journal of Hepatology, 2019, 70, 449-457.	3.7	102
17	Development of shellfish allergy after exposure to dual immune checkpoint blockade. Hepatic Oncology, 2018, 5, HEP02.	4.2	3
18	Gut microbiomeâ€“mediated bile acid metabolism regulates liver cancer via NKT cells. Science, 2018, 360, .	12.6	931

#	Article	IF	Citations
19	Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2018, 67, 1305-1315.	4.2	93
20	Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4+ T cell apoptosis promoting HCC development. Cell Death and Disease, 2018, 9, 620.	6.3	90
21	Establishment of Orthotopic Liver Tumors by Surgical Intrahepatic Tumor Injection in Mice with Underlying Non-Alcoholic Fatty Liver Disease. Methods and Protocols, 2018, 1, 21.	2.0	14
22	Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 536-554.	17.8	158
23	Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes. OncoTargets and Therapy, 2017, Volume 10, 2389-2401.	2.0	36
24	Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer. , 2017, 5, 93.		56
25	Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives. European Journal of Cancer, 2016, 59, 160-170.	2.8	78
26	Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1. Frontiers in Oncology, 2014, 4, 92.	2.8	22
27	Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells. OncoTargets and Therapy, 2013, 6, 1119.	2.0	16
28	Checkpoint Inhibitors Modulate Plasticity of Innate Lymphoid Cells in Peripheral Blood of Patients With Hepatocellular Carcinoma. Frontiers in Immunology, 0, 13, .	4.8	4